A new Lancet Psychiatry review examined 54 randomized trials of cannabinoids for mental disorders and substance use disorders, and the evidence was thinner than many public claims suggest. A few outcomes showed signals, especially in cannabis use disorder, sleep-time outcomes in insomnia, tic severity, and autism-related measures, but much of the literature remained low certainty and short-term. This physician-guided review explains what the paper actually found, what it did not test, and how to think about the gap between clinical enthusiasm and evidence quality.
THC Panic Symptoms: Why Weed Can Feel Like Panic
THC panic symptoms often begin in the body before they become a fearful thought. This blog explains how cannabis can increase heart rate, intensify body awareness, and trigger a spiral of misread alarm signals, especially in newer or more anxiety-sensitive users.
CBD and Liver Enzymes: What the New JAMA Study Actually Shows
A new peer-reviewed study sent ripples through the CBD world—but what does it actually say about liver health? Spoiler: it’s not as simple as “CBD is dangerous.” When you zoom in on the details, the real story is about dose, data, and the difference between panic and perspective.
Cannabis Interactions with Drugs and Clinical Considerations
Cannabis Interactions with Drugs and Clinical Considerations Cannabis use has become more prevalent in recent years. With increasing legalization of cannabis, it is crucial for both medical and recreational users to be...